Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02128763 · ClinicalTrials.gov registry record · Phase 3
Dry Eye Assessment and Management Study
A Phase 3 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 3
- Development phase
- 535
- Enrollment target
NCT02128763: Completed Phase 3 study, sponsored by University of Pennsylvania.
NCT02128763 is a Phase 3 study that has completed, run by University of Pennsylvania. The registered enrollment target is 535 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02128763, a Phase 3 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 535 participants
- Enrollment target
Study Summary
The objective of the DREAM study is to evaluate the effectiveness and safety of supplementation with omega-3 fatty acids in relieving the symptoms of moderate to severe dry eye disease.
Interventions
- DRUG Placebo
- DRUG Omega-3 supplements
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 535 participants |
| Start Date | 2014-11 |
| Est. Completion | 2020-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02128763
The ClinicalTrials.gov registry entry for NCT02128763 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 535 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02128763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02128763 about?
NCT02128763 is a clinical study titled "Dry Eye Assessment and Management Study". The objective of the DREAM study is to evaluate the effectiveness and safety of supplementation with omega-3 fatty acids in relieving the symptoms of moderate to severe dry eye disease.
What is the current status of trial NCT02128763?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 535 participants. The study started on 2014-11. Estimated completion is 2020-01-31.
What interventions are being tested in trial NCT02128763?
The interventions under investigation include: Placebo (DRUG), Omega-3 supplements (DRUG).
Who is sponsoring clinical trial NCT02128763?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.